Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177957 · ClinicalTrials.gov registry record
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
A clinical trial of Gram-negative Bacterial Infections, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT00177957: Completed study of Gram-negative Bacterial Infections, sponsored by University of Pittsburgh.
NCT00177957 is a study of Gram-negative Bacterial Infections that has completed, run by University of Pittsburgh. The registered enrollment target is 600 participants, above the 292-participant average among 4 other Gram-negative Bacterial Infections trials with a reported enrollment target (105% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177957, a study of Gram-negative Bacterial Infections, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this study are to: * Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the risk factors for failure of prompt clearance of the blood of Gram negative bacteria * Determine the survival of patients with Gram negative bacteremia * Determine if failure of prompt clearance of the blood of Gram negative bacteria is a predictor of mortality following this infection
Primary Outcome
dead or alive
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-04 |
| Est. Completion | 2016-05 |
What the finished NCT00177957 record still lists
NCT00177957 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 292-participant average among 4 other Gram-negative Bacterial Infections trials with a reported enrollment target (105% higher).
The record links to 1 condition, with Gram-negative Bacterial Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00177957 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177957 about?
NCT00177957 is a clinical study titled "Gram Negative Bacteremia, Risk Factors for Failure of Therapy". The aims of this study are to: * Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli * Determine the risk factors for failure of prompt clearance of t...
What is the current status of trial NCT00177957?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2005-04. Estimated completion is 2016-05.
What conditions does trial NCT00177957 study?
This clinical trial studies the following conditions: Gram-negative Bacterial Infections.
Who is sponsoring clinical trial NCT00177957?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177957 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gram-negative Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
RECRUITING · Phase 2
-
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
COMPLETED
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
COMPLETED · Phase 2
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia